Abcam founder Jonathan Milner said he’d vote against Danaher’s proposed buyout of the biopharma tools supplier on Thursday, and the UK company appeared dumbfounded by the timing of his move.
Abcam “considers it surprising that Dr. Milner has taken active steps to oppose the deal without reviewing the full details in the Scheme Circular,” the company said in its Thursday response, referring to the documents it will submit “in the coming weeks” that outline the background of the $5.7 billion transaction, the bidding process involved and the advice of its board and bankers.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.